Rituximab plus telitacicept for ANCA vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old, and can be any gender
- You have been newly diagnosed or are in a relapse of GPA or MPA, based on 2022 ACR/EULAR classification
- Your vasculitis is severe and actively causing problems right now (meets 2021 ACR/VF criteria)
- Your PR3-ANCA test is positive (at diagnosis or during your disease)
- You have not previously stopped rituximab due to side effects or intolerance
- You are not pregnant (or planning pregnancy in the next 2 years) and you do not have certain serious infections or major organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
This trial tests a new type of cell therapy called anti-CD19 CAR-T cells for people with active ANCA vasculitis that hasn't gotten better with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.